Lung disease

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).   Saracatinib worked as well or better than two approved drugs at reducing tissue scarring in preclinical models of IPF according to the study published in the American Journal of Respiratory and Critical Care Medicine.   Researchers at National Jewish […]

Brainomix has partnered with Bridge Biotherapeutics to deliver AI imaging biomarker analysis within the Phase II study of novel autotaxin inhibitor BBT-877 in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT (HRCT) data in patients with […]

DDW was delighted to work with CN Bio on an exclusive event which focused on novel approaches to human lung disease modelling.  The free event took place on 29 March at 3pm.  It covered:  Accelerating the discovery of new therapeutics for treatment of lung injuries using patho/physiology mimicking models. (Speaker Professor Wojciech Chrzanowski, Faculty of […]